The Institute for Clinical and Economic Review says new CGRP inhibitor treatments for chronic and episodic migraine probably won’t be cost effective. But the analysis omits five important components.
View the Graphic
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.